The efficacy of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review
DOI:
https://doi.org/10.33448/rsd-v9i11.9648Keywords:
Ulcerative colitis; Fecal microbiota transplantation; Patient; Intervention.Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease restricted to the mucosa, characterized by diarrhea and most often accompanied by major bleeding. The usual current treatment, demonstrating low efficacy, thus, the fecal microbiota transplant (FMT) was proposed as a therapy option. Given the above, the objective of this article is to evaluate the effectiveness of TMF for the treatment of active UC. The research was structured by the PICO methodology (Patient, Intervention, Comparison and Result), inclusion and exclusion criteria and assessment of reliability and quality by Jadad and Chochrane tool. The results were favorable regarding the use of FMT for the treatment of mild and moderately active UC, however, the route of administration, the time of treatment and the identification of the microbial profile necessary for the clinical remission of the disease were divergent in some studies. Through the analysis it was possible to conclude that the FMT has potential in order to provide benefits to patients with UC and more research in the area is necessary to define the best type of treatment for each patient.
References
Adams, S. M., et al. (2013). Ulcerative colitis. American family physician, 87(10), 699–705. Recuperado de <https://www.aafp.org/afp/2013/0515/p699.html>.
Benech, N., et al., (2019). Fecal Microbiota Transplantation for Ulcerative Colitis. JAMA, 321(22), 2240, Recuperado de <https://jamanetwork.com/journals/jama/article-abstract/2735489>.
Carvalho, A. P. V. C. (2013). Avaliação do risco de viés de ensaios clínicos randomizados pela ferramenta da colaboração Cochrane. Revista Diagnóstico & Tratamento. 18(1), 38-44. Recuperado de < http://files.bvs.br/upload/S/1413-9979/2013/v18n1/a3444.pdf>.
Chen, W. X., et al. (2014). Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World Journal of Gastroenterology, 20(42), 15657-15763. Recuperado de <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229530/>.
Costello, S. P., et al. (2019). Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA. [S.l.], 321(2), 156-164, Recuperado de <https://jamanetwork.com/journals/ja ma/fullarticle/2720727>.
Fuentes, S., et al. (2017) Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME Journal, 11(8), 1877-89. Recuperado de <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520032/>.
Jadad, A. R., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clinical Trials. 17(1), 1-12.
Koche, J. C. (2011). Fundamentos de metodologia científica. Petrópolis: Vozes. http://www.brunovivas.com/wp-content/uploads/sites/10/2018/07/K%C3%B6che-Jos%C 3%A9-Carlos0D0AFundamentos-de-metodologia-cient%C3%ADfica-_-teoria-da0D0 Aci%C3%AAncia-e-inicia%C3%A7%C3%A3o-%C3%A0-pesquisa.pdf.
Ludke, M., & Andre, M. E. D. A. (2013). Pesquisas em educação: uma abordagem qualitativa. São Paulo: E.P.U. Recuperado de https://edisciplinas.usp.br/pluginfile.php/4 091392/mod_resource/content/1/Lud_And_cap3.pdf.
Moayyedi, P., et al. (2015). Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 49(1), 102-109. Recuperado de <https://www.gastrojournal.org/article/S0016-5085(15)00451-5/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F25857665%2F>.
Neeraj, N., et al. (2017). Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflammatory Bowel Diseases. 23(10), 1702-1709. Recuperado de < https://academic.oup.com/ibdjournal/ar ticle/23/10/1702/4791645>.
Ordás, I., et al. (2012) Ulcerative colitis. The Lancet, [S.l.], 380(9853), 1606-1619. Recuperado de < https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60150-0/fulltext>.
Paramsothy, S., et al. (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. [S.l.], 389(10075), 1218-1228. Recuperado de <https://www.thelancet.com/journals/lan cet/article/PIIS0140-6736(17)30182-4/fulltext>.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da Pesquisa Científica. [e-book]. Ed. UAB/NTE/UFSM. Santa Maria/RS. Recuperado de http://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_MetodologiaPesquisaCientifica.pdf?sequence=1.
Rossen, N. G., et al.(2015). Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. [S.l.], 149(1) 110-118. Recuperado de <https://www.gastrojournal.org/article/S0016-5085(15)00448-5/fulltext?refer rer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F25836986%2F>.
Shi, Y., et al. (2016). Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PloS one. [S.l.], 11(6), 1-23. Recuperado de < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905678/>.
Tian, Y., et al. (2019). Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study. BMC Gastroenteroogyl, 19(1169), 1-12. Recuperado de < https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-019-1010-4>.
Vindigni, S. M. et al. (2017). Fecal Microbiota Transplantation. Gastroenterology clinics of North America, 46(1), 171–185. Recuperado de <https://scihub.wikicn.top/10.101 6/j.gtc.2016.09.012>.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Marcela Jorge Bozza; Julia Maria Moreira Vilar; Dora Inés Kozusny-Andreani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
